Loading
Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.
Developed by IASO Bio with Innovent from work at Tongji Hospital in Wuhan, and approved by the NMPA in June 2023 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug. The FUMANBA-1 trial (JAMA Oncology 2024) reported objective responses in about 96% of infused patients with deep, minimal residual disease-negative remissions and a low rate of severe cytokine release syndrome. It competes in China with ciltacabtagene autoleucel and zevorcabtagene autoleucel; it also holds FDA regenerative medicine advanced therapy designation.
Autologous T cells expressing a fully human BCMA-directed single-chain variable fragment with 4-1BB co-stimulation, lentivirally transduced; the fully human binder is designed to reduce anti-CAR immunity and allow persistence. Connects to BCMA.
1.Equecabtagene autoleucel slips into a pocket on BCMA.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2023 | Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One trial page and one treatment page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this drug: (TITLE:"Equecabtagene autoleucel" OR ABSTRACT:"Equecabtagene autoleucel" OR TITLE:"Fucaso" OR ABSTRACT:"Fucaso" OR TITLE:"eque-cel" OR ABSTRACT:"eque-cel" OR TITLE:"CT103A" OR ABSTRACT:"CT103A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Equecabtagene autoleucel, not a curated reading list.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares Michael Yu (Yu De-Chao), Innovent Biologics and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares Innovent Biologics and the tag china.
Shares Innovent Biologics and the tag china.
Shares Innovent Biologics and the tag china.